Home › Compare › TELDF vs ABBV
TELDF yields 8.26% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TELDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TELDF + ABBV for your $10,000?
Telefónica Deutschland Holding AG provides integrated telecommunication services to private and business customers in Germany. It offers mobile and stationery voice and data services; very high data rate digital subscriber line (VDSL) internet services; fiber-to-the-home lines; broadband services, consisting of VDSL, cable, fiber, and fixed mobile substitution services; and machine to machine communication and managed connectivity services. The company also distributes various terminal devices, such as mobile phones; and offers digital products and services in the fields of Internet of Things, as well as O2 Tv, O2 cloud, and O2 Select & Stream. In addition, it provides access to infrastructure and services for its wholesale partners. The company provides its products and services through a network of independently operated franchise and premium partner shops, and online and telesales channels, as well as indirect selling channels, such as partnerships and co-operations with retailers. It markets its products and services under the O2, Blau, AY YILDIZ, Ortel Mobile, Telefonica, and Geeny brand names. As of December 31, 2021, Telefónica Deutschland Holding AG served approximately 45.7 million mobile accesses and 2.3 million fixed-line customers. The company was formerly known as Telefónica Germany Verwaltungs GmbH and changed its name to Telefónica Deutschland Holding AG in September 2012. The company is based in Munich, Germany. Telefónica Deutschland Holding AG is a subsidiary of Telefonica Germany Holdings Limited.
Full TELDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.